These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 20920304)

  • 1. Scoring of senescence signalling in multiple human tumour gene expression datasets, identification of a correlation between senescence score and drug toxicity in the NCI60 panel and a pro-inflammatory signature correlating with survival advantage in peritoneal mesothelioma.
    Lafferty-Whyte K; Bilsland A; Cairney CJ; Hanley L; Jamieson NB; Zaffaroni N; Oien KA; Burns S; Roffey J; Boyd SM; Keith WN
    BMC Genomics; 2010 Oct; 11():532. PubMed ID: 20920304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.
    Sciarrillo R; Wojtuszkiewicz A; El Hassouni B; Funel N; Gandellini P; Lagerweij T; Buonamici S; Blijlevens M; Zeeuw van der Laan EA; Zaffaroni N; Deraco M; Kusamura S; Würdinger T; Peters GJ; Molthoff CFM; Jansen G; Kaspers GJL; Cloos J; Giovannetti E
    EBioMedicine; 2019 Jan; 39():215-225. PubMed ID: 30581150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro.
    Borchert S; Wessolly M; Schmeller J; Mairinger E; Kollmeier J; Hager T; Mairinger T; Herold T; Christoph DC; Walter RFH; Eberhardt WEE; Plönes T; Wohlschlaeger J; Aigner C; Schmid KW; Mairinger FD
    BMC Cancer; 2019 Jan; 19(1):108. PubMed ID: 30700254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential Susceptibility of Human Pleural and Peritoneal Mesothelial Cells to Asbestos Exposure.
    Dragon J; Thompson J; MacPherson M; Shukla A
    J Cell Biochem; 2015 Aug; 116(8):1540-52. PubMed ID: 25757056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression of mesothelioma in vinylidene chloride-exposed F344/N rats reveal immune dysfunction, tissue damage, and inflammation pathways.
    Blackshear PE; Pandiri AR; Nagai H; Bhusari S; Hong HH; Ton TV; Clayton NP; Wyde M; Shockley KR; Peddada SD; Gerrish KE; Sills RC; Hoenerhoff MJ
    Toxicol Pathol; 2015 Feb; 43(2):171-85. PubMed ID: 24958746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response.
    Lund-Andersen C; Nakken S; Nygård S; Fromm B; Aasheim LB; Davidson B; Julsrud L; Abrahamsen TW; Kristensen AT; Dybdahl B; Larsen SG; Hovig E; Flatmark K
    Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30862609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent DNA damage-induced premature senescence alters the functional features of human bone marrow mesenchymal stem cells.
    Minieri V; Saviozzi S; Gambarotta G; Lo Iacono M; Accomasso L; Cibrario Rocchietti E; Gallina C; Turinetto V; Giachino C
    J Cell Mol Med; 2015 Apr; 19(4):734-43. PubMed ID: 25619736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular senescence in the development and treatment of cancer.
    Saretzki G
    Curr Pharm Des; 2010 Jan; 16(1):79-100. PubMed ID: 20214620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of TGFBI in mesothelioma and breast cancer: association with tumor suppression.
    Li B; Wen G; Zhao Y; Tong J; Hei TK
    BMC Cancer; 2012 Jun; 12():239. PubMed ID: 22695319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammation-driven senescence-associated secretory phenotype in cancer-associated fibroblasts enhances peritoneal dissemination.
    Yasuda T; Koiwa M; Yonemura A; Miyake K; Kariya R; Kubota S; Yokomizo-Nakano T; Yasuda-Yoshihara N; Uchihara T; Itoyama R; Bu L; Fu L; Arima K; Izumi D; Iwagami S; Eto K; Iwatsuki M; Baba Y; Yoshida N; Ohguchi H; Okada S; Matsusaki K; Sashida G; Takahashi A; Tan P; Baba H; Ishimoto T
    Cell Rep; 2021 Feb; 34(8):108779. PubMed ID: 33626356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma.
    Davidson B; Zhang Z; Kleinberg L; Li M; Flørenes VA; Wang TL; Shih IeM
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):5944-50. PubMed ID: 17062665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma.
    Cioce M; Ganci F; Canu V; Sacconi A; Mori F; Canino C; Korita E; Casini B; Alessandrini G; Cambria A; Carosi MA; Blandino R; Panebianco V; Facciolo F; Visca P; Volinia S; Muti P; Strano S; Croce CM; Pass HI; Blandino G
    Oncogene; 2014 Nov; 33(46):5319-31. PubMed ID: 24240684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantifying Senescence-Associated Phenotypes in Primary Multipotent Mesenchymal Stromal Cell Cultures.
    Nadeau S; Cheng A; Colmegna I; Rodier F
    Methods Mol Biol; 2019; 2045():93-105. PubMed ID: 31020633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targetable mechanisms driving immunoevasion of persistent senescent cells link chemotherapy-resistant cancer to aging.
    Muñoz DP; Yannone SM; Daemen A; Sun Y; Vakar-Lopez F; Kawahara M; Freund AM; Rodier F; Wu JD; Desprez PY; Raulet DH; Nelson PS; van 't Veer LJ; Campisi J; Coppé JP
    JCI Insight; 2019 Jun; 5(14):. PubMed ID: 31184599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors.
    Kalra N; Ashai A; Xi L; Zhang J; Avital I; Raffeld M; Hassan R
    Oncol Rep; 2012 Jun; 27(6):1794-800. PubMed ID: 22426987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features.
    Marqués M; Tranchant R; Risa-Ebrí B; Suárez-Solís ML; Fernández LC; Carrillo-de-Santa-Pau E; Del Pozo N; Martínez de Villarreal J; Meiller C; Allory Y; Blum Y; Pirker C; Hegedus B; Barry ST; Carnero A; Berger W; Jean D; Real FX
    Cancer Res; 2020 Feb; 80(4):843-856. PubMed ID: 31911549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cmap-enabled gene expression signature-matching approach identifies small-molecule inducers of accelerated cell senescence.
    Wu D; Pepowski B; Takahashi S; Kron SJ
    BMC Genomics; 2019 Apr; 20(1):290. PubMed ID: 30987592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MLL1 is essential for the senescence-associated secretory phenotype.
    Capell BC; Drake AM; Zhu J; Shah PP; Dou Z; Dorsey J; Simola DF; Donahue G; Sammons M; Rai TS; Natale C; Ridky TW; Adams PD; Berger SL
    Genes Dev; 2016 Feb; 30(3):321-36. PubMed ID: 26833731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Major carcinogenic pathways identified by gene expression analysis of peritoneal mesotheliomas following chemical treatment in F344 rats.
    Kim Y; Ton TV; DeAngelo AB; Morgan K; Devereux TR; Anna C; Collins JB; Paules RS; Crosby LM; Sills RC
    Toxicol Appl Pharmacol; 2006 Jul; 214(2):144-51. PubMed ID: 16460773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells.
    Zanellato I; Colangelo D; Osella D
    Curr Cancer Drug Targets; 2018; 18(8):816-828. PubMed ID: 28669341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.